Trial Profile
A randomized, double-blind study to assess the efficacy and safety of prophylactic use of maribavir [Camvia] versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Maribavir (Primary) ; Ganciclovir
- Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
- Focus Registrational; Therapeutic Use
- Sponsors Shire; ViroPharma Incorporated
- 13 Feb 2009 Status changed from active, no longer recruiting to discontinued, as reported in a ViroPharma media release..
- 13 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Aug 2007 New trial record.